Clinical trial
Vaccine Treatment for Advanced Non-Small Cell Lung Cancer
NCT00073398 · NewLink Genetics Corporation, Industry · Completed
Key facts
| NCT number | NCT00073398 |
|---|---|
| Title | Vaccine Treatment for Advanced Non-Small Cell Lung Cancer |
| Official title | A Phase I/II Study of Tergenpumatucel-L (HyperAcute Lung) an Antitumor Vaccination Using Alpha (1,3) Galactosyltransferase Expressing Allogeneic Tumor Cells in Patients With Refractory or Recurrent Non-Small Cell Lung Cancer |
| Lead sponsor | NewLink Genetics Corporation, Industry |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Non-small Cell Carcinoma, Adenocarcinoma of Lung, Squamous Cell Carcinoma, Large Cell Carcinoma, Lung Neoplasms |
| Intervention type | Biological |
| Interventions | Drug: Hyperacute Lung Cancer Cell Vaccine |
| Enrollment | 54 |
| Start date | Nov 1, 2003 |
| Primary completion | Nov 1, 2012 |
| Completion | Mar 1, 2013 |
| First posted | Nov 20, 2003 |
| Last update posted | May 28, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: